Company Profile
Addex Therapeutics Stock Price, News & Analysis
- Ticker:
- ADXN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Switzerland and trades in the U
Stock performance
5.80 USD (+1.93%)
Close
Last updated: August 6, 2026
8.1M USD
Market cap
Why the stock is moving
Current closing-price context is not available for ADXN.
Company overview
Allosteric Modulator Developer
Addex Therapeutics develops small-molecule allosteric modulators for neurological disorders. Its strategy combines internally controlled programs, partnered assets, and economic exposure to a broader pipeline advanced through the Neurosterix spinout.
Internally Controlled Programs
Lead candidate dipraglurant is an mGlu5 negative allosteric modulator with potential applications in recovery from brain injury, stroke, and traumatic brain injury. Addex also has a GABAB positive allosteric modulator program for chronic cough.
Partnered Development Model
Indivior is developing an Addex-originated GABAB PAM for substance use disorders. This partnership model allows Addex to retain program economics while external collaborators fund and operate selected development programs.
Neurosterix Exposure
Addex holds a 20% interest in Neurosterix, which is advancing M4 PAM and mGlu7 NAM programs for schizophrenia, psychosis, mood disorders, and other central nervous system conditions.
Future catalysts
Phase 1 data for Neurosterix’s M4 PAM candidate NTX-253 are expected in summer 2026.
Recent news
- 01
- 02
Addex Shareholders Approve All Resolutions at Annual General Meeting
Source: Addex Therapeutics
- 03
Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Source: Addex Therapeutics
- 04
- 05
Addex Convenes Annual General Meeting 2026
Source: Addex Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Addex Therapeutics (ADXN)?
Addex Therapeutics (ADXN) most recently closed at 5.80 USD, a +1.93% move versus the previous session.
What is the market cap of Addex Therapeutics (ADXN)?
Addex Therapeutics currently has a market capitalization of 8.1M USD on BioPharmSignal.
What does Addex Therapeutics do?
Allosteric Modulator Developer Addex Therapeutics develops small-molecule allosteric modulators for neurological disorders. Its strategy combines internally controlled programs, partnered assets, and economic exposure to a broader pipeline advanced through the Neurosterix spinout. Internally Controlled Programs Lead candidate dipraglurant is an mGlu5...
On which exchange is ADXN stock listed?
Addex Therapeutics (ADXN) is associated with NASDAQ, Switzerland and trades in the U, Biopharma.
What is NTX-253?
Phase 1 data for Neurosterix’s M4 PAM candidate NTX-253 are expected in summer 2026.
Which conditions is Addex Therapeutics targeting with NTX-253?
Phase 1 data for Neurosterix’s M4 PAM candidate NTX-253 are expected in summer 2026.
How does Addex Therapeutics describe recent progress with NTX-253?
Phase 1 data for Neurosterix’s M4 PAM candidate NTX-253 are expected in summer 2026.
What is Allosteric?
Allosteric Modulator Developer Addex Therapeutics develops small-molecule allosteric modulators for neurological disorders.